Kane Biotech Inc.

As of June 30, 2026, Kane Biotech Inc. carries a market capitalization of 6.15M, placing it among publicly traded companies globally. Its enterprise value stands at 7.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kane Biotech Inc. has 205.06M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 142.53, and the price-to-book ratio stands at -6.19.

These figures are as of June 30, 2026. The EV/Sales ratio of 187.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.26M versus a market cap of 6.15M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kane Biotech Inc. maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -197.52, indicating conservative leverage, while an interest coverage ratio of -13.78 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -89.50, reflecting losses generated across the asset base. Inventory turnover of 0.10 indicates how many times Kane Biotech Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Kane Biotech Inc. recorded 8,080.00 in income tax expense. The company reported a pretax loss of -2.80M and -2.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 25, 2026, Kane Biotech Inc.'s stock has declined approximately 37.50% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.09.

Over the twelve months ended June 30, 2026, Kane Biotech Inc. generated 38,720.00 in revenue and converted that into -2.70M in net income, yielding earnings per share of -0.01. EBITDA reached -2.57M, while operating income came in at -2.68M.

As of June 30, 2026, Kane Biotech Inc. holds 854,729.00 in cash and equivalents against 1.96M in total debt, resulting in a net debt position of 1.11M. Total book value stands at -993,863.00, with working capital of -988,701.00 providing operational flexibility.

Kane Biotech Inc. produced -2.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -72,634.00 in capital expenditures, free cash flow totaled -2.57M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Kane Biotech Inc. posted a gross margin of -0.04, reflecting its pricing power and cost economics. The operating margin of -6,908.88 and net profit margin of -6,980.02 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Kane Biotech Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -46.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.50, meaning Kane Biotech Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Kane Biotech Inc.'s most recent stock split took place on March 13, 2017 with a 5:1 split ratio.

As of June 30, 2026, Kane Biotech Inc. has an Altman Z-Score of -37.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.